Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Koji Kato et al.|Nature Medicine|2021Cited by 523
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaChan Y. Cheah, John F. Seymour, Kirsten Herbert et al.|British Journal of Cancer|2014Cited by 132
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Tara Graff et al.|Blood|2024Cited by 132
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)Catherine Thiéblemont, Nathan Fowler, M. Dreyling et al.|Hematological Oncology|2025Cited by 1
A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)Krish Patel, Gilles Salles, Hong‐Mei Han et al.|Blood|2025Cited by 0